List of Excipients in Branded Drug INTUNIV

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	CELLULOSE, MICROCRYSTALLINE
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	CROSPOVIDONE
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	FUMARIC ACID
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	GLYCERYL DIBEHENATE
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	HYPROMELLOSE 2208
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	LACTOSE MONOHYDRATE
Takeda Pharmaceuticals America Inc	INTUNIV	guanfacine	54092-513	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

Intuniv Excipient Strategy and Commercial Opportunities for Guanfacine Extended-Release Tablets

Last updated: August 1, 2026

Intuniv is guanfacine hydrochloride extended-release, a once-daily, nonstimulant treatment for attention-deficit/hyperactivity disorder. Its commercial value is tied to controlled release, pediatric usability, dose flexibility, and predictable exposure rather than to a novel active ingredient. The strongest excipient opportunities are modified-release matrix systems, robust tablet processing, pediatric swallowability, and differentiated 505(b)(2) products. Standard generic substitution has already reduced the value of the original brand franchise.

What is Intuniv and how does its formulation work?

Intuniv contains guanfacine hydrochloride in 1 mg, 2 mg, 3 mg, and 4 mg extended-release tablets. The product is administered once daily and must be swallowed whole. The FDA label prohibits crushing, chewing, or breaking the tablets because these actions can alter the release profile.[1]

Guanfacine is an alpha-2A adrenergic receptor agonist. Intuniv is approved for ADHD in patients ages 6 to 17 years, either as monotherapy or as adjunctive therapy to stimulant medication.[1]

The formulation objective is to reduce the rapid exposure associated with immediate-release guanfacine and provide sustained systemic delivery over the dosing interval. The excipient system must therefore control:

• Drug release across gastrointestinal pH conditions
• Tablet mechanical strength
• Dose uniformity at low drug loading
• Stability during storage
• Consistent pharmacokinetics after food intake
• Pediatric acceptability without encouraging tablet manipulation

What inactive ingredients are used in Intuniv?

The Intuniv label identifies a conventional solid oral excipient platform that includes hydrophilic and film-forming polymers, fillers, binders, disintegrants, glidants, and lubricants. The principal inactive ingredients listed in FDA labeling include hypromellose, methacrylic acid copolymer, lactose monohydrate, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, and magnesium stearate.[1]

The formulation architecture can be characterized as follows:

Functional role	Intuniv excipient category	Commercial purpose
Release control	Hypromellose and acrylic copolymer	Slows hydration, diffusion, and drug release
Dilution and tablet mass	Lactose monohydrate and microcrystalline cellulose	Supports dose uniformity and compression
Binding	Povidone	Improves granule and tablet integrity
Disintegration	Crospovidone	Supports mechanical breakup after the release phase
Flow improvement	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubrication	Magnesium stearate	Reduces ejection force and tooling adhesion
Film coating	Polymer-based coating system	Supports identification, handling, and product protection

The exact quantitative composition and manufacturing parameters remain important because generic applicants must demonstrate comparable release and bioequivalence. Matching the ingredient list alone does not reproduce the product.

What excipient strategy protects the Intuniv release profile?

The main technical protection is the interaction between polymer level, polymer grade, tablet porosity, compression force, granulation conditions, and drug particle characteristics. A generic or reformulated product can use different excipients, but it must produce an equivalent clinical and pharmacokinetic profile under FDA requirements.

How do hydrophilic matrix polymers affect guanfacine release?

Hypromellose hydrates after contact with gastrointestinal fluid and forms a gel layer. The gel regulates water penetration and drug diffusion. Higher-viscosity grades generally slow release, although the result depends on polymer concentration, particle size, compression, and the solubility of the drug.

Methacrylic acid copolymers are pH-responsive polymers. Depending on grade and concentration, they can reduce release in acidic conditions and permit greater release at higher intestinal pH. In an extended-release tablet, the polymer may contribute to release control, film integrity, or both.

For guanfacine, polymer selection must account for:

1. Low dose strength relative to total tablet mass.
2. The risk of dose dumping after tablet damage.
3. Food-related changes in gastrointestinal transit and drug absorption.
4. Interpatient variability in pediatric gastrointestinal physiology.
5. Compatibility with wet granulation, dry granulation, or direct compression.

Polymer suppliers can create commercial value through optimized grades, premixes, particle engineering, and technical packages that reduce formulation-development time.

Which excipient variables are most important for generic development?

The highest-value critical material attributes are:

• Hypromellose viscosity grade
• Acrylic polymer grade and neutralization behavior
• Polymer concentration
• Lactose-to-cellulose ratio
• Povidone molecular weight
• Crospovidone particle size
• Magnesium stearate concentration and blending time
• Tablet porosity and tensile strength
• Drug particle-size distribution
• Coating weight gain

The most sensitive critical process parameters are usually granulation endpoint, drying moisture, lubrication time, compression force, tablet hardness, and coating conditions.

A supplier that can provide design-of-experiment data linking these variables to dissolution and pharmacokinetics has a stronger commercial position than a supplier selling an undifferentiated commodity excipient.

What formulation opportunities exist for Intuniv and guanfacine extended release?

The primary opportunity is a differentiated guanfacine extended-release product rather than a simple tablet copy. Several development paths are technically plausible.

Can a multiparticulate guanfacine formulation improve commercial value?

Multiparticulate systems using coated pellets, mini-tablets, or granules could provide more uniform gastrointestinal distribution than a single matrix tablet. They may also support:

• Sprinkle administration over soft food
• Lower sensitivity to local gastrointestinal conditions
• More reproducible release after partial tablet damage
• Flexible dose combinations
• Pediatric administration for patients who cannot swallow tablets

A multiparticulate product would likely require a new drug application or a 505(b)(2) pathway, depending on the degree of reliance on guanfacine reference-product data and the formulation claims. The regulatory pathway would depend on the proposed dosage form, labeling, clinical bridging, and bioequivalence strategy.

Is a liquid or orally disintegrating guanfacine product commercially attractive?

A liquid suspension, oral solution, orally disintegrating tablet, or mini-tablet could address pediatric administration barriers. These products face important technical constraints:

• Guanfacine dose accuracy at low concentrations
• Sedimentation or crystal growth in suspensions
• Taste masking
• Chemical and microbial stability
• Preservation
• Dose measurement errors
• Avoidance of unintended immediate release

A liquid formulation that simply delivers guanfacine immediately would not be an Intuniv equivalent. It would resemble immediate-release guanfacine and could have a different pharmacokinetic and safety profile. A commercially credible liquid opportunity would need controlled release, clear dosing instructions, and a regulatory position that supports the proposed exposure profile.

Can excipients support an abuse-deterrent or tamper-resistant product?

The commercial rationale is limited compared with opioid products, but formulation robustness can reduce the effect of crushing, chewing, or tablet fragmentation. Potential technologies include:

• High-viscosity polymer matrices
• Swellable hydrophilic systems
• Multiparticulate coatings
• Harder compression matrices
• Polymer networks that limit rapid extraction

The product label already instructs patients not to crush, chew, or break Intuniv.[1] Any tamper-resistant claim would require product-specific performance data and FDA review. A supplier should not assume that a controlled-release polymer automatically supports an abuse-deterrence claim.

What patents protect Intuniv and its excipient technology?

Intuniv’s original market protection came primarily from the extended-release guanfacine formulation and related regulatory exclusivity, not from a broad patent right over individual excipients. The patent estate historically included U.S. patents covering guanfacine extended-release dosage forms and methods of use. The principal product patents listed in the FDA Orange Book expired before or around the period when generic guanfacine extended-release products entered the market, subject to patent-term adjustments, pediatric extensions, and litigation outcomes recorded at the time.[2]

The commercial implications are clear:

• Hypromellose, lactose, cellulose, povidone, crospovidone, and magnesium stearate are established excipients and are not proprietary to Intuniv.
• A generic manufacturer can generally use alternative excipients if it demonstrates pharmaceutical equivalence and bioequivalence.
• Formulation patents may still matter for a specific new product, improved dosage form, manufacturing process, or pediatric administration method.
• An excipient supplier cannot rely on Intuniv’s historical patents to create a continuing exclusivity position for a standard polymer or filler.

What is the Orange Book status of Intuniv?

Intuniv was approved under NDA 022037. FDA Orange Book records identify the reference listed drug and approved strengths, while generic guanfacine hydrochloride extended-release products are listed through abbreviated new drug applications.[2] The original brand’s commercial exclusivity has been overtaken by generic competition.

The Orange Book should be reviewed for current patent listings, withdrawal status, and the specific reference product used for any proposed ANDA. Patent status can change through expiration, delisting, certifications, or regulatory updates.

When did Intuniv lose exclusivity?

Intuniv lost practical market exclusivity when FDA-approved generic guanfacine extended-release tablets became available. Generic entry followed patent litigation and settlement activity involving the brand owner and ANDA applicants. The exact timing of commercial launch varied by applicant and strength.

The relevant distinction is between:

Protection type	Intuniv position
New chemical entity exclusivity	Not the current commercial barrier
Pediatric exclusivity	Historical, limited-duration protection
Formulation patents	Historically relevant; core protection has expired or been overtaken by generic entry
Orange Book-listed patents	Must be checked against current FDA records
Generic substitution	Available for approved guanfacine ER products, subject to state substitution rules
Regulatory exclusivity today	No effective brand-level barrier comparable to the original launch period

Which companies challenge or compete with Intuniv?

The principal competitors are generic manufacturers of guanfacine hydrochloride extended-release tablets. FDA-approved generic competition has included large and specialty generic companies that filed ANDAs against the Intuniv reference product.[2] The competitive field is defined by:

• Approval of the 1 mg, 2 mg, 3 mg, and 4 mg strengths
• Therapeutic equivalence designation
• Manufacturing reliability
• Wholesale acquisition cost
• Medicaid and managed-care contracts
• Availability across all strengths
• Supply continuity during pediatric treatment cycles

The relevant branded competitors are not direct formulation copies. They include stimulant ADHD products such as methylphenidate and amphetamine formulations, as well as atomoxetine and clonidine extended-release. Guanfacine ER competes on nonstimulant positioning, once-daily dosing, and use in patients for whom stimulant therapy is unsuitable or insufficient.

How does Intuniv compare with Kapvay?

Intuniv contains guanfacine extended release, while Kapvay contains clonidine hydrochloride extended release. Both are nonstimulant ADHD treatments, but their pharmacology and tolerability profiles differ.

Attribute	Intuniv	Kapvay
Active ingredient	Guanfacine hydrochloride	Clonidine hydrochloride
Drug class	Alpha-2A adrenergic agonist	Central alpha-2 adrenergic agonist
Dosage form	Extended-release tablet	Extended-release tablet
Main formulation challenge	Controlled guanfacine release	Controlled clonidine release
Pediatric opportunity	Swallowability and dose titration	Swallowability and dose titration
Generic exposure	High	High
Excipient opportunity	Improved release control and alternate dosage forms	Similar, but molecule-specific release and PK requirements apply

Guanfacine’s longer effective duration and alpha-2A selectivity create a different product profile from clonidine. A formulation designed for Kapvay cannot be transferred directly to guanfacine without comparative dissolution and pharmacokinetic work.

What commercial opportunities exist for excipient suppliers?

The largest opportunities are formulation-enabling products that solve a measurable development or manufacturing problem.

1. Modified-release polymer platforms

Suppliers can offer hypromellose and acrylic polymer systems optimized for low-dose, once-daily tablets. Value increases when the supplier provides:

• Grade selection by viscosity and particle size
• Dissolution modeling
• Compression and granulation guidance
• Food-effect development support
• Scale-up data
• Regulatory documentation

2. Pediatric multiparticulate systems

Coated pellets and mini-tablets could enable sprinkle dosing, dose flexibility, and improved administration. Commercial differentiation depends on maintaining extended release without requiring the child to swallow a conventional tablet.

3. Taste-masking systems

Taste masking is relevant to chewable, orally disintegrating, liquid, and sprinkle products. Ion-exchange resins, polymer coatings, lipid barriers, and pH-responsive coatings can reduce guanfacine bitterness. These systems must not materially change the intended release profile.

4. Direct-compression platforms

A direct-compression excipient blend can reduce manufacturing steps and improve batch-to-batch consistency. The main requirements are:

• Low-dose content uniformity
• Adequate flow
• Low segregation risk
• Controlled tablet porosity
• Reproducible dissolution after scale-up

A co-processed filler-binder containing microcrystalline cellulose, lactose, or a comparable diluent may have value if it reduces granulation dependence without changing drug release.

5. Continuous manufacturing

Guanfacine ER is a candidate for continuous manufacturing research because the product has a relatively low drug load and a formulation-sensitive release profile. Continuous blending and compression can improve residence-time control and reduce batch variability. The development burden includes process analytical technology, blend uniformity monitoring, and validation of residence-time distribution.

What generic launch risks exist for guanfacine extended release?

Generic applicants face moderate formulation risk and substantial commercial pressure.

Risk	Business effect
Dissolution mismatch	ANDA review delay or additional studies
Food-effect difference	Potential failure to demonstrate comparable exposure
Dose dumping after crushing	Safety and labeling concern
Low-dose content uniformity failure	Batch rejection or regulatory deficiency
Excessive tablet hardness	Incomplete release or poor disintegration
Excessive porosity	Faster release and pharmacokinetic mismatch
Polymer variability	Batch-to-batch dissolution drift
Generic price erosion	Limited return on formulation investment
Pediatric administration barriers	Lower adherence and weaker product differentiation
Manufacturing concentration	Supply interruption risk

For a conventional ANDA, the commercial ceiling is constrained by therapeutic equivalence and generic pricing. A differentiated 505(b)(2) product can capture more value, but it requires clinical, pharmacokinetic, device, or usability evidence that supports a meaningful labeling or administration advantage.

What FDA regulatory issues apply to Intuniv excipient development?

FDA evaluates the finished dosage form, not only the safety history of each excipient. Established excipients may have favorable regulatory status, but their use level, route, dosage form, and patient population still matter.

Key regulatory issues include:

• Pharmaceutical equivalence for ANDA products
• Comparative dissolution across multiple media and pH conditions
• Single-dose and, where required, multiple-dose bioequivalence
• Food-effect assessment
• Dose proportionality across strengths
• Tablet manipulation studies
• Pediatric safety and administration data
• Excipient qualification at proposed exposure levels
• Stability-indicating analytical methods
• Manufacturing process validation

FDA’s guidance on extended-release oral dosage forms emphasizes that release behavior and pharmacokinetic performance must be assessed as an integrated product system.[3] A formulation that matches the reference product’s listed excipients but produces a different release curve remains a regulatory risk.

How strong is the patent and formulation estate for Intuniv?

The original Intuniv estate had meaningful value because extended release converted immediate-release guanfacine into a once-daily ADHD product. Its current defensive strength is low against ordinary generic substitution because the core product has generic competition and the original exclusivity period has passed.

The stronger future position would come from a new, separately protected product with one or more of the following characteristics:

• A distinct multiparticulate dosage form
• A validated sprinkle administration method
• A pediatric liquid with controlled release
• A new combination product
• A manufacturing process that produces a clinically relevant product advantage
• A formulation that improves food-effect consistency
• A novel release profile supported by clinical evidence

Patentability would depend on novelty, nonobviousness, written description, enablement, and claim scope. Merely replacing one conventional filler with another would generally provide a weak patent position.

What licensing and partnering opportunities exist?

Licensing opportunities are more attractive around enabling technology than around the legacy Intuniv brand. Potential counterparties include:

• Generic manufacturers seeking lower-cost extended-release platforms
• Specialty pharmaceutical companies developing pediatric ADHD products
• Excipient suppliers with proprietary co-processed systems
• Contract development and manufacturing organizations
• Companies pursuing 505(b)(2) reformulations
• Drug-delivery companies with multiparticulate or taste-masking technology

A commercially credible deal would focus on measurable outcomes such as fewer manufacturing steps, improved dissolution robustness, a new administration route, or reduced bioequivalence risk. A license based solely on use of common excipients would have limited negotiating value.

What geographic opportunities remain?

The United States is a mature generic market. Opportunities in Europe, Canada, Japan, and emerging markets depend on local approval status, patent history, reference-product availability, and ADHD treatment patterns.

Geographic diligence should cover:

• National patent expiration and supplementary protection rights
• Local pediatric labeling
• Reference-product requirements
• Bioequivalence standards
• Permitted excipient grades
• Import and manufacturing controls
• Generic substitution rules
• Reimbursement and stimulant access
• Availability of guanfacine immediate-release products

A formulation platform with global excipient documentation can reduce regional filing friction. The largest barrier is usually not excipient availability but demonstration of equivalent modified-release performance under each regulator’s requirements.

Key Takeaways

• Intuniv is a guanfacine hydrochloride extended-release tablet approved for ADHD in pediatric patients.
• Its excipient strategy centers on hypromellose, acrylic polymer, lactose, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, and magnesium stearate.
• The key technical asset is the integrated release-control system, not any single excipient.
• Conventional generic competition has materially reduced the value of the original Intuniv franchise.
• The strongest commercial opportunities are pediatric multiparticulates, sprinkle products, controlled-release liquids, orally disintegrating systems, taste masking, and manufacturing platforms.
• An excipient supplier can create defensible value through formulation data, scale-up support, and regulatory packages.
• A new 505(b)(2) product could command more value than an ordinary ANDA, but it would require a clinically relevant administration or performance advantage.
• Standard excipient substitution alone is unlikely to support a strong patent or premium commercial position.

FAQs

Is Intuniv an extended-release excipient product or an active pharmaceutical product?

Intuniv is a finished drug product containing guanfacine hydrochloride as the active ingredient. Its extended-release performance comes from the combined formulation and manufacturing system.

Can guanfacine extended-release tablets be made with different excipients?

Yes. A generic manufacturer may use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and safety.

Does Intuniv contain lactose?

The FDA-approved Intuniv labeling identifies lactose monohydrate among the inactive ingredients.[1] Manufacturers developing alternative products must evaluate lactose exposure, labeling, compatibility, and patient acceptability.

Is a guanfacine ER liquid automatically equivalent to Intuniv?

No. A liquid formulation must demonstrate an appropriate release profile and comparable exposure. An immediate-release guanfacine liquid would not automatically be equivalent to Intuniv.

Can a new Intuniv formulation receive patent protection?

Yes, if it contains patentable subject matter such as a novel dosage form, release system, administration method, manufacturing process, or clinically supported performance advantage. Routine substitution of common excipients would generally provide limited patent strength.

References

1. U.S. Food and Drug Administration. (2023). Intuniv (guanfacine) extended-release tablets prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Guidance for industry.